HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation.

Abstract
Hematopoietic stem cell transplantation is usually performed without considering the ABO compatibility between donor and recipient. There are few studies analyzing ABO matching impact on transfusion outcome of umbilical cord blood transplantation (UCBT) recipients. The aim of this study was to analyze factors influencing transfusion outcome, highlighting the ABO matching between donor and recipient. This study has reviewed data from 318 patients who underwent single unit UCBT at la Fe University Hospital from January 2000 to December 2014. There were no differences between RBC and platelet (PLT) requirements or RBC and PLT transfusion independence according to ABO matching between donor and recipient. RBC and PLT requirements were statistically correlated (ρ=0,841, P<0.001). A total of 170 and 188 patients achieved RBC and PLT independence, respectively, within 180 days after UCBT. Persistence of recipient isoagglutinins was detected in 6.8% of patients with major ABO incompatibility at median of 176 days (103-269) after UCBT. Autoimmune haemolytic anemia was diagnosed in 15 patients, 12 of them due to cold antibodies. In conclusion, ABO matching has not influenced transfusion requirements of patients undergoing UCBT.
AuthorsP Solves, N Carpio, C Carretero, J I Lorenzo, J Sanz, I Gómez, F López-Chuliá, M J Arilla, A I Regadera, P Montesinos, G F Sanz, M Á Sanz
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 52 Issue 3 Pg. 394-399 (Mar 2017) ISSN: 1476-5365 [Electronic] England
PMID27797368 (Publication Type: Journal Article)
Chemical References
  • ABO Blood-Group System
Topics
  • ABO Blood-Group System
  • Adolescent
  • Adult
  • Aged
  • Allografts
  • Blood Group Incompatibility
  • Blood Grouping and Crossmatching
  • Cord Blood Stem Cell Transplantation
  • Female
  • Hematologic Neoplasms (therapy)
  • Humans
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: